从指南到智能:人工智能如何优化甲状腺结节活检决策
回顾性分析454例患者548个符合ACR TI-RADS活检指征的甲状腺结节,比较单用ACR TI-RADS与联合Demetics系统(De TI-RADS)的活检率。联合系统将活检率从70.6%降至48.1%,不必要活检率从47.5%降至17.4%,漏诊率从11.0%降至4.4%,阳性预测值从52.5%升至82.6%,差异均有统计学意义(p<0.05)。
要点
- 联合Demetics系统后活检率由70.6%(387/548)降至48.1%(264/548)。
- 不必要活检率由47.5%(184/387)降至17.4%(46/265),漏诊率由11.0%(25/228)降至4.4%(10/228)。
- 阳性预测值由52.5%(203/387)升至82.6%(218/264)。
核心结论
- ACR TI-RADS联合Demetics系统可改善结节风险评估,降低不必要活检和漏诊并提高阳性预测值。
研究设计与样本
- 回顾性研究分析454例患者548个甲状腺结节,全部符合ACR TI-RADS指南活检指征(分类≥3且直径≥10 mm),用联合ACR TI-RADS与Demetics系统的De TI-RADS重新分类并比较活检率。
诊断标准与关键数值
- 单用ACR TI-RADS活检率70.6%(387/548)、阳性预测值52.5%(203/387)、不必要活检率47.5%(184/387)、漏诊率11.0%(25/228)。
临床应用与阅片要点
- 作者认为联合ACR TI-RADS与Demetics系统可提高诊断效能和效率,为临床医生和患者提供更可靠的工具。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate the value of combining American College of Radiology (ACR) Thyroid Imaging Reporting and Data System (TI-RADS) with the Demetics ultrasound diagnostic system in reducing the rate of fine-needle aspiration (FNA) biopsies for thyroid nodules.
METHODS: A retrospective study analyzed 548 thyroid nodules from 454 patients, all meeting ACR TI-RADS guidelines (category ≥3 and diameter ≥10 mm) for FNA. Nodule was reclassified using the combined ACR TI-RADS and Demetics system (De TI-RADS), and the biopsy rates were compared.
RESULTS: Using ACR TI-RADS alone, the biopsy rate was 70.6% (387/548), with a positive predictive value (PPV) of 52.5% (203/387), an unnecessary biopsy rate of 47.5% (184/387) and a missed diagnosis rate of 11.0% (25/228). Incorporating Demetics reduced the biopsy rate to 48.1% (264/548), the unnecessary biopsy rate to 17.4% (46/265) and the missed diagnosis rate to 4.4% (10/228), while increasing PPV to 82.6% (218/264). All differences between ACR TI-RADS and De TI-RADS were statistically significant (p < 0.05).
CONCLUSION: The integration of ACR TI-RADS with the Demetics system improves nodule risk assessment by enhancing diagnostic and efficiency. This approach reduces unnecessary biopsies and missed diagnoses while increasing PPV, offering a more reliable tool for clinicians and patients.
引用
- Zeng W, He Y, Xu R, et al. From Guidelines to Intelligence: How AI Refines Thyroid Nodule Biopsy Decisions. Ultrasound Med Biol. 2025. PMID: 40451670. doi:10.1016/j.ultrasmedbio.2025.05.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。